Bio-Path Holdings

Bio-Path Holdings is an oncology-focused biotech developing non-toxic, targeted cancer therapies for fragile patients ineligible for standard chemotherapy. Its core innovation is the DNAbilize® liposomal delivery platform, designed to concentrate antisense drugs at the tumor site while sparing healthy tissue. The company's strategy centers on advancing its lead asset, prexigebersen, in AML while exploring its platform's utility in solid tumors and other blood cancers through earlier-stage candidates. Recent leadership changes aim to revitalize clinical progress and corporate strategy.

Proprietary DNAbilize® platform: a liposomal nanoparticle delivery system designed for the targeted systemic delivery of antisense oligonucleotides to cancer cells, aiming to concentrate therapeutic effect and reduce systemic toxicity.

Faces intense competition in AML from established targeted therapies and novel agents. Competes with larger, better-funded companies in the antisense/oligonucleotide and nanoparticle delivery spaces. Differentiation hinges entirely on demonstrating a superior safety/efficacy profile in clinical trials.